Viewing Study NCT06454968

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:25 PM
Ignite Modification Date: 2026-01-01 @ 4:14 AM
Study NCT ID: NCT06454968
Status: RECRUITING
Last Update Posted: 2024-06-18
First Post: 2024-05-27
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Sponsor: Peking Union Medical College Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Marginal Zone Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Orelabrutinib View
None Marginal Zone Lymphoma View
None obinutuzumab View
None lenalidomide View